Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis

Guest Editor
Maria Concetta Fagnoli, L’Aquila, Italy

8 figures and 1 table, 2019
Sponsor Note
The supplement was funded by Novartis Farma Italy.

Disclosure Statement Guest Editor
Maria Concetta Fargnoli has no conflicts of interest to declare.

S. Karger
Medical and Scientific Publishers
Basel • Freiburg • Hartford • Oxford •
Bangkok • Dubai • Kuala Lumpur •
Melbourne • Mexico City •
Moscow • New Delhi • Paris •
Shanghai • Tokyo
www.karger.com

Disclaimer
The statements, opinions and data contained in
this publication are solely those of the individual
authors and contributors and not of the publish-
er and the editor(s). The appearance of advertise-
ments in the journal is not a warranty, endorse-
ment, or approval of the products or services
advertised or of their effectiveness, quality or
safety. The publisher and the editor(s) disclaim
responsibility for any injury to persons or prop-
erty resulting from any ideas, methods, instruc-
tions or products referred to in the content or ad-
vertisements.

Drug Dosage
The authors and the publisher have exerted every
effort to ensure that drug selection and dosage set
forth in this text are in accord with current rec-
ommendations and practice at the time of pub-
lication. However, in view of ongoing research,
changes in government regulations, and the con-
stant flow of information relating to drug therapy
and drug reactions, the reader is urged to check
the package insert for each drug for any change
in indications and dosage and for added warn-
ings and precautions. This is particularly impor-
tant when the recommended agent is a new and/
or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into
other languages, reproduced or utilized in any
form or by any means, electronic or mechanical,
including photocopying, recording, microcopy-
ing, or by any information storage and retrieval
system, without permission in writing from the
publisher or, in the case of photocopying, direct
payment of a specified fee to the Copyright Clear-
ance Center (see ‘General Information’).

© Copyright 2019 by S. Karger AG,
P.O. Box, CH-4009 Basel (Switzerland)
Editorial

1 Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
Fargnoli, M.C. (L’Aquila, Italy)

Single Case

4 Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi’s Varicelliform Eruption
Campanati, A.; Molinelli, E.; Brisigotti, V.; Brancorsini, D.; Bobyr, I.; Diotallevi, F.; Radi, G.; Offidani, A. (Ancona, Italy)

Case and Review

11 Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
Gambardella, A. (Naples, Italy)

17 Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report
Kostaki, D.; Aquila, E.; Macaluso, L.; Mattozzi, C.; Richetta, A.G. (Rome, Italy)

Case Series

23 Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
Ribero, S.; Licciardello, M.; Quaglino, P.; Dapavo, P. (Turin, Italy)

Case and Review

29 Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
Tiberio, R.; Graziola, F.; Miglino, B.; Veronese, F.; Annali, G.; Savoia, P. (Novara, Italy)